

## TOZAAR AT

### **For the use of a Registered Medical Practitioner or a Hospital or Laboratory only**

Abbreviated Prescribing information for Tozaar AT (Losartan Potassium 50mg and Atenolol 50mg Tablets) [Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

**PHARMACOLOGICAL PROPERTIES: Losartan:** Losartan potassium is an angiotensin II receptor (type AT1) antagonist. **Atenolol:** Atenolol is a beta-blocker which is beta1-selective, (i.e. acts preferentially on beta1-adrenergic receptors in the heart). **INDICATION:** In the treatment of mild to moderate hypertension when monotherapy of either drug fails. **Atenolol:** Hypertension, Angina pectoris, Cardiac arrhythmias, Myocardial infarction. Early intervention in the acute phase. **Losartan:** Hypertension, Hypertensive patients with left ventricular hypertrophy, Renal protection in type 2 diabetic patients with nephropathy (microalbuminuria). **DOSAGE AND ADMINISTRATION**The recommended dose is one tablet once daily with or without meal. Dosage must be individualized on the basis of both effectiveness and tolerance for each individual component in the treatment of proposed indications. **CONTRINDICATIONS: Losartan:** In patients who are hypersensitive to any component of this product. Do not co-administer aliskiren with Losartan in patients with diabetes. **Atenolol:** cardiogenic shock, uncontrolled heart failure, sick sinus syndrome, second or third degree heart block, untreated pheochromocytoma, metabolic acidosis, bradycardia (<45bpm), hypotension, known hypersensitivity to the active substance, or any of the excipients and severe peripheral arterial circulatory disturbances. **WARNINGS & PRECAUTIONS: Losartan:** Fetal toxicity (include skull hypoplasia, anuria, hypotension, renal failure, and death), hypotension, hypersensitivity: angioedema, impaired hepatic function: patient receiving losartan should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician. **atenolol:** in patients who have congestive heart failure controlled by digitalis and/or diuretics, atenolol should be administered cautiously. Patients with hepatic insufficiency; bradycardia and heart block and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. Atenolol should be used with caution in diabetic patients and in patients with bronchospastic disease, thyrotoxicosis, untreated pheochromocytoma, pregnancy and fetal injury, electrolyte and fluid balance status. **DRUG INTERACTION: Losartan:** Rifampin, Fluconazole, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium, lithium, NSAIDs, Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren. **Atenolol:** Catecholamine-depleting drugs (eg, reserpine); Calcium channel blockers; clonidine; prostaglandin synthase inhibiting drugs, eg, indomethacin. **ADVERSE REACTIONS:** Asthenia/fatigue, edema/swelling, abdominal pain, chest pain, nausea, headache, pharyngitis, diarrhea, dyspepsia, myalgia, insomnia, cough, sinus disorder, fever, orthostatic effects, syncope, angina pectoris, second degree AV block, hypotension, myocardial infarction, arrhythmias including atrial fibrillation, palpitation, sinus bradycardia, tachycardia, ventricular fibrillation, anorexia, constipation, dental pain, dry mouth, flatulence, gastritis, vomiting, anemia, gout, arm pain, hip pain, joint swelling, knee pain, musculoskeletal pain, shoulder pain, stiffness, arthralgia, arthritis, fibromyalgia, muscle weakness, anxiety, ataxia, confusion, depression, dream abnormality, hypesthesia, decreased libido, memory impairment, migraine, nervousness, paresthesia, peripheral neuropathy, panic disorder, sleep disorder, somnolence, tremor, vertigo, dyspnea, bronchitis, pharyngeal discomfort, epistaxis, rhinitis, respiratory congestion, alopecia, dermatitis, dry skin, ecchymosis, erythema, flushing, photosensitivity, pruritus, rash, sweating, urticarial, blurred vision, burning/stinging in the eye, conjunctivitis, taste perversion, tinnitus, impotence, nocturia, urinary frequency, urinary tract infection, malaise,

hyperkalemia, hyponatremia, rhabdomyolysis, cold extremities, raynaud's phenomenon, nightmares, hepatic toxicity, purpura, thrombocytopenia, psoriasiform skin reactions, and an increase in ANA (antinuclear antibodies).

**MARKETED BY:**



**TORRENT PHARMACEUTICALS LTD.**  
Torrent House, Off Ashram Road,  
Ahmedabad-380 009, INDIA

**IN/ TOZAAR AT 50mg/Oct-2015/01/AbPI**  
(Additional information is available on request)